PharmaEssentia (TPE:6446) Cyclically Adjusted Revenue per Share: NT$10.59 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6446 PharmaEssentia Corp TPE:6446
84 GF Score
Price NT$1,180.00
GF Value NT$1,124.67
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is PharmaEssentia Cyclically Adjusted Revenue per Share?

PharmaEssentia TPE:6446 +0.43% 84 Cyclically Adjusted Revenue per Share is NT$10.59 as of Mar. 2026. GuruFocus rates TPE:6446 with a GF Score™ of 84/100 and a GF Value™ of NT$1,124.67 (Fairly Valued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

PharmaEssentia's adjusted revenue per share for the three months ended in Mar. 2026 was NT$12.408. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$10.59 for the trailing ten years ended in Mar. 2026.

During the past 12 months, PharmaEssentia's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-23), PharmaEssentia's current stock price is NT$1180.00. PharmaEssentia's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was NT$10.59. PharmaEssentia's Cyclically Adjusted PS Ratio of today is 111.43.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of PharmaEssentia was 175.26. The lowest was 48.66. And the median was 95.80.


PharmaEssentia  (TPE:6446) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

PharmaEssentia's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1180.00/10.59
=111.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of PharmaEssentia was 175.26. The lowest was 48.66. And the median was 95.80.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


PharmaEssentia Cyclically Adjusted Revenue per Share Related Terms


PharmaEssentia Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for PharmaEssentia's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaEssentia Cyclically Adjusted Revenue per Share Chart

PharmaEssentia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 3.06 5.23 9.17

PharmaEssentia Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.09 7.01 8.01 9.17 10.59

TPE:6446 vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, PharmaEssentia's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaEssentia Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PharmaEssentia's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where PharmaEssentia's Cyclically Adjusted PS Ratio falls into.


TPE:6446
84GF Score
PharmaEssentia Corp TPE:6446
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaEssentia Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, PharmaEssentia's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=12.408/330.2130*330.2130
=12.408

Current CPI (Mar. 2026) = 330.2130.

PharmaEssentia Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.009 241.018 0.012
201609 0.004 241.428 0.005
201612 0.006 241.432 0.008
201703 0.002 243.801 0.003
201706 0.005 244.955 0.007
201709 0.002 246.819 0.003
201712 0.005 246.524 0.007
201803 0.002 249.554 0.003
201806 0.004 251.989 0.005
201809 0.002 252.439 0.003
201812 0.086 251.233 0.113
201903 0.128 254.202 0.166
201906 0.249 256.143 0.321
201909 0.006 256.759 0.008
201912 0.699 256.974 0.898
202003 0.003 258.115 0.004
202006 0.464 257.797 0.594
202009 0.420 260.280 0.533
202012 0.892 260.474 1.131
202103 0.301 264.877 0.375
202106 0.268 271.696 0.326
202109 0.288 274.310 0.347
202112 1.116 278.802 1.322
202203 0.793 287.504 0.911
202206 2.834 296.311 3.158
202209 2.320 296.808 2.581
202212 2.268 296.797 2.523
202303 2.390 301.836 2.615
202306 3.142 305.109 3.401
202309 3.528 307.789 3.785
202312 4.054 306.746 4.364
202403 4.026 312.332 4.256
202406 5.705 314.175 5.996
202409 6.730 315.301 7.048
202412 7.437 315.605 7.781
202503 7.925 319.799 8.183
202506 8.756 322.561 8.964
202509 9.460 324.800 9.618
202512 11.841 324.054 12.066
202603 12.408 330.213 12.408

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$10.59 mean?
PharmaEssentia (TPE:6446) has a Cyclically Adjusted Revenue per Share of NT$10.59 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on PharmaEssentia and its competitors.
Is PharmaEssentia's Cyclically Adjusted Revenue per Share too high?
PharmaEssentia's current Cyclically Adjusted Revenue per Share is NT$10.59. Overall, PharmaEssentia has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PharmaEssentia's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
PharmaEssentia's Cyclically Adjusted Revenue per Share of NT$10.59 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on PharmaEssentia and its competitors. PharmaEssentia's current Cyclically Adjusted Revenue per Share is NT$10.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaEssentia stock overvalued right now?
Based on GuruFocus' analysis, PharmaEssentia (TPE:6446) is currently considered Fairly Valued. The stock's GF Value™ is NT$1,124.67, compared to a current price of NT$1,180.00 — trading 4.9% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$10.59. PharmaEssentia's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For PharmaEssentia (TPE:6446), the current Cyclically Adjusted Revenue per Share is NT$10.59 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PharmaEssentia (TPE:6446) Overvalued in 2026?

Based on GuruFocus' analysis, PharmaEssentia stock appears to be overvalued. The current stock price of NT$1,180.00 is trading 4.9% above its estimated GF Value™ of NT$1,124.67. GuruFocus considers PharmaEssentia to be Fairly Valued.

Key valuation signals for TPE:6446:

  • Cyclically Adjusted Revenue per Share: NT$10.59
  • GF Value™: NT$1,124.67 vs. price of NT$1,180.00 (4.9% above fair value)
  • GF Score™: 84/100 with 5 warning signs

No single metric tells the full story. See the TPE:6446 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PharmaEssentia Business Description

Address 13th Floor, No.3, Park Street, Nangang District, Taipei, TWN, 115
PharmaEssentia Corp engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API and new drug patterns developments. Its products include BESREMi, Ropeginterferon alfa-2b, Ropeg + anti PD-1, PEG-IL-2, PEG-Cytokines, PD-1-IL-2v, NY-ESO-1 TCR-T, among others. It derives revenue from medicine products sales from contracts with customers.
84GF Score

Get the complete analysis for TPE:6446

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$1,180.00
Price
NT$1,124.67
GF Value